Informed consent documents from U.S. psilocybin clinical trials often emphasize mental health and physical risks but rarely include psychedelic-specific elements like ineffability or therapeutic touch, despite calls from bioethicists for tailored consent forms. A content analysis of 28 documents from 13 sites found good coder reliability. The results suggest that while general risks are well covered, the unique features of psychedelic experiences are not consistently addressed in consent materials. The authors recommend ongoing debate about which elements are most important for potential participants to consider when deciding whether to join a study.
Informed consent is intended to give potential study participants clear information about risks and benefits, but participants often misunderstand key aspects of what they are told. The paper examines the persistent problem of participant misconceptions in medical and psychological research, discussing how these misunderstandings undermine the ethical goals of informed consent and suggesting possible reasons and remedies.